NovMetaPharma Co (XKRX:229500) ROE % Adjusted to Book Value : -4.71% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is NovMetaPharma Co ROE % Adjusted to Book Value?

NovMetaPharma Co's ROE % for the quarter that ended in Dec. 2024 was -152.95%. NovMetaPharma Co's PB Ratio for the quarter that ended in Dec. 2024 was 32.45. NovMetaPharma Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -4.71%.

NovMetaPharma Co ROE % Adjusted to Book Value Historical Data

The historical data trend for NovMetaPharma Co's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovMetaPharma Co ROE % Adjusted to Book Value Chart

NovMetaPharma Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-0.73

-46.12

-4.71

NovMetaPharma Co Semi-Annual Data
	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial					-0.73	-	-	-46.12	-4.71

Competitive Comparison of NovMetaPharma Co's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, NovMetaPharma Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovMetaPharma Co's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NovMetaPharma Co's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where NovMetaPharma Co's ROE % Adjusted to Book Value falls into.

Save Embed

NovMetaPharma Co ROE % Adjusted to Book Value Calculation

NovMetaPharma Co's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-152.95%	/	32.45
	=	-4.71%

NovMetaPharma Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-152.95%	/	32.45
	=	-4.71%

NovMetaPharma Co ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of NovMetaPharma Co's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

NovMetaPharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » ROE % Adjusted to Book Value

Traded in Other Exchanges

N/A

Address

727 13, Gangnam-gu, Seoul eonju layer, Seoul, KOR

Website

http://www.novmeta.com

NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.

NovMetaPharma Co Headlines

No Headlines